This article describes the protocol of a multicenter, randomized, double-blind, placebo-controlled clinical trial to assess the efficacy of Fuzhiqing Ointment in mild to moderate atopic dermatitis. The study includes 210 patients from 10 hospitals in China, recruitment takes place from September 2025 to February 1, 2026. The intervention group (n=140) uses urea cream with vitamin E combined with Fuzhiqing ointment, the control group (n=70) the same cream with placebo, application twice a day for 2 weeks, followed by 4 weeks observation. The primary endpoint is the proportion of patients with a ≥50% improvement in EASI score (EASI50) at week 2. Secondary outcomes include changes in EASI, NRS, IGA, DLQI, and ADCT at weeks 1 and 2, as well as EASI, NRS, and adverse events at week 6. Ethical approval obtained December 2024, registration ChiCTR2500095971, recruitment started February 2025, ending February 2026, analysis from May 2026, results until December 2026. Fuzhiqing Ointment contains 15 traditional Chinese herbs with anti-inflammatory, anti-pruritic and anti-infective properties.